Galectin Therapeutics (GALT) Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Galectin Therapeutics (GALT) Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis StreetInsider.com Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis Proactive Investors USA & Canada Full coverage